Filter your search
- $995.00 – $1,990.00Gene and chromosome testing for inherited diseases currently represents the third largest molecular diagnostics testing segment in the U.S. Assays in this market address applications in genetic carrier and predisposition testing. Currently, most testing is for prenatal screening and for assessing clinically suspect newborns for various chromosomal abnormalities (e.g., Down’s syndrome, fragile X syndrome). Some […]October 1, 2004$995.00 – $1,990.00Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular […]October 1, 2004$995.00 – $1,990.00The field of pharmacogenetics promises to open up new opportunities for the diagnostic industry at the same time it opens the door to more effective therapeutics. Pharmacogenetics is based on the principle that the effects of a given medication when administered to a patient are determined, at least in part, by his or her genetic […]October 1, 2004$895.00 – $1,790.00There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the […]October 1, 2004$3,500.00 – $7,000.00With an aging population in the United States, the incidence of prevalence of age-related diseases and disorders is expected to mount rapidly over the next decade. Since senior citizens already consume a disproportionate amount of healthcare dollars, the economic picture will only go from bad to worse insofar as healthcare is concerned. The solution to […]September 1, 2004$3,500.00 – $7,000.00Neural and muscular stimulation by electronic and magnetic means have evolved into a burgeoning product development and commercial fields. For decades, transcutaneous electronic nerve stimulation (TENS) has been a mainstay in the pain relief arsenal. Through the years, as biocompatibility problems were being solved, electrode and sensor implants developed into a multitude of technologies with […]September 1, 2004$895.00 – $1,790.00Nanotechnology is no longer a bench-top curiosity. It is becoming a real commercial force for a variety of applications. This market briefing discusses the state of play in the race to commercialize products and forecasts likely market scenarios. The briefing forecasts the market in generally promising areas such as cancer therapeutics, specialized drug delivery, diagnostics, […]September 1, 2004$1,995.00 – $5,990.00The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents […]August 1, 2004$3,500.00 – $7,000.00This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail. The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These […]August 1, 2004$995.00 – $1,910.00Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ […]August 1, 2004